Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 731 to 740 of 1090 total matches.
Olopatadine (Patanase) Nasal Spray
The Medical Letter on Drugs and Therapeutics • Jun 30, 2008 (Issue 1289)
of
Medicine
CONTRIBUTING EDITOR, DRUG INTERACTIONS: Philip D. Hansten,
Pharm.D., University of Washington ...
Olopatadine 0.6% nasal spray (Patanase - Alcon) has been approved by the FDA for treatment of seasonal allergic rhinitis in patients ≥ 12 years old. An H1-antihistamine with mast-cell stabilizing activity, olopatadine is already marketed for treatment of allergic conjunctivitis in a 0.1% solution as Patanol and in a 0.2% solution as Pataday. Azelastine (Astelin), another H1-antihistamine with mast-cell stabilizing activity, has been available for intranasal treatment of allergic rhinitis since 1997.
Vedolizumab (Entyvio) for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Sep 15, 2014 (Issue 1451)
) for use during
pregnancy.
DRUG INTERACTIONS — Concomitant use of vedolizumab
with TNF inhibitors should ...
The FDA has approved vedolizumab (Entyvio - Takeda),
an intravenous integrin receptor antagonist, for treatment
of moderate to severe ulcerative colitis or Crohn's
disease in adults who have not responded to, lost
response to, or cannot tolerate standard treatment.
Natalizumab (Tysabri), another integrin receptor antagonist,
has been available for several years for treatment
of Crohn's disease and multiple sclerosis.
Cobicistat (Tybost) and Combinations for HIV
The Medical Letter on Drugs and Therapeutics • Nov 23, 2015 (Issue 1482)
and atazanavir.
DRUG INTERACTIONS — Cobicistat is an inhibitor
of CYP3A and 2D6, and of the drug transporters ...
Cobicistat, a pharmacokinetic enhancer that boosts
levels of some HIV drugs but has no antiretroviral
activity of its own, is now available alone as Tybost
(Gilead) and in fixed-dose combinations with the
protease inhibitors atazanavir (Evotaz — BMS) and
darunavir (Prezcobix — Janssen) for treatment of
HIV-1 infection. Both atazanavir and darunavir have
traditionally been used in combination with the
CYP3A inhibitor ritonavir (Norvir) to boost their serum
concentrations, but neither is available in a fixed-dose
combination with ritonavir.
Vericiguat (Verquvo) for Heart Failure
The Medical Letter on Drugs and Therapeutics • Mar 08, 2021 (Issue 1619)
differences between the two groups in the
rates of symptomatic hypotension or syncope.
DRUG INTERACTIONS ...
The FDA has approved vericiguat (Verquvo – Merck),
an oral soluble guanylate cyclase (sGC) stimulator,
to reduce the risk of hospitalization for heart failure
and cardiovascular (CV) death following a worsening
heart failure event (hospitalization for heart failure or
treatment with IV diuretics as an outpatient) in patients
with symptomatic chronic heart failure and left
ventricular ejection fraction (LVEF) <45%. Vericiguat
is the second sGC stimulator to be marketed in the
US. Riociguat (Adempas), which is FDA-approved
for treatment of pulmonary arterial hypertension...
Oxymetazoline Cream (Rhofade) for Rosacea
The Medical Letter on Drugs and Therapeutics • May 22, 2017 (Issue 1521)
has been detected in the milk of lactating rats.
DRUG INTERACTIONS – Theoretically, systemic
absorption ...
The FDA has approved the selective alpha1A-adrenergic
receptor agonist oxymetazoline as a 1% cream (Rhofade
– Allergan) for topical treatment of persistent facial
erythema of rosacea in adults. Brimonidine, a selective
alpha2-adrenergic receptor agonist, was approved in
2013 as a 0.33% gel (Mirvaso) for the same indication.
Like Mirvaso, Rhofade is not indicated for treatment of
inflammatory lesions of rosacea. Oxymetazoline has
been available over the counter for many years as a
nasal decongestant spray (Afrin, and others).
Baricitinib (Olumiant) for Severe Alopecia Areata
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
before starting
treatment.
DRUG INTERACTIONS — Coadministration of the
strong organic anion ...
The oral Janus kinase (JAK) inhibitor baricitinib
(Olumiant – Lilly), which was previously approved by
the FDA for treatment of moderately to severely active
rheumatoid arthritis and treatment of COVID-19 in
certain hospitalized adults, has now been approved
for treatment of severe alopecia areata in adults.
Baricitinib is the first systemic treatment to be
approved in the US for this indication.
Idelalisib (Zydelig) for Chronic Lymphocytic Leukemia and Non-Hodgkins Lymphoma (online only)
The Medical Letter on Drugs and Therapeutics • May 11, 2015 (Issue 1468)
.
DRUG INTERACTIONS — Idelalisib should not be
used with other drugs that can cause hepatic toxicity ...
The FDA has approved idelalisib (Zydelig – Gilead),
an oral kinase inhibitor, for use in combination with
rituximab (Rituxan) for treatment of relapsed chronic
lymphocytic leukemia (CLL). It is also approved as
monotherapy for treatment of relapsed follicular
lymphoma and relapsed small lymphocytic lymphoma
(both are subtypes of indolent non-Hodgkins
lymphoma) in patients who have received at least two
prior systemic therapies.
Buprenorphine Buccal Film (Belbuca) for Chronic Pain
The Medical Letter on Drugs and Therapeutics • Apr 11, 2016 (Issue 1492)
is stopped or maternal buprenorphine
use is discontinued.
DRUG INTERACTIONS — Buprenorphine is metabolized ...
Belbuca (Endo), a buccal formulation of the partial
opioid agonist buprenorphine, has been approved by the
FDA for management of pain severe enough to require
daily, around-the-clock, long-term opioid treatment.
Buprenorphine is also available as a transdermal patch
(Butrans) and in a parenteral formulation (Buprenex, and
generics) for treatment of pain. A sublingual formulation
of buprenorphine and buccal and sublingual formulations
containing buprenorphine and the opioid antagonist
naloxone are approved for use as alternatives to
methadone for treatment of opioid...
Onzetra Xsail - Sumatriptan Nasal Powder
The Medical Letter on Drugs and Therapeutics • Jul 18, 2016 (Issue 1499)
12 hours after taking the drug.
DRUG INTERACTIONS — Administration of sumatriptan ...
The FDA has approved Onzetra Xsail (Avanir), a nasal
powder formulation of sumatriptan, for acute treatment
of migraine in adults. Nasal spray formulations of
sumatriptan (Imitrex) and zolmitriptan (Zomig) have
been available for many years.
Alfuzosin (Uroxatral) -- Another Alpha1-blocker for Benign Prostatic Hyperplasia
The Medical Letter on Drugs and Therapeutics • Jan 05, 2004 (Issue 1173)
means and imposes fines of up to $25,000 for violations.
DRUG INTERACTIONS — Inhibitors of CYP3A4 ...
Alfuzosin hydrochloride (Uroxatral - Sanofi-Synthelabo) is now available in the US in a new formulation for once-daily treatment of benign prostatic hyperplasia (BPH). The drug has been used in Europe since 1987. Alpha1-blockers cause relaxation of smooth muscle tone in the bladder neck, prostatic capsule and prostatic urethra, relieving symptoms of urinary obstruction.